Zobrazeno 1 - 10 of 80 pro vyhledávání: '"Julie A. Stein"'
1
Akademický článek
Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial
Autor: Bin Li, Jun Li, Tian Chen, Uwe M Martens, Lazar Vujanovic, Rom Leidner, Robert L Ferris, William Sharfman, Chrisann Kyi, Suzanne L Topalian, Janis M Taube, Christine H Chung, William C Spanos, Anthony Gonçalves, Lot A Devriese, Helene Gauthier, Simon I Chiosea, Julie E Stein, Adam Barrows
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
Background Head and neck squamous cell carcinomas (HNSCCs) are common malignancies caused by carcinogens, including tobacco and alcohol, or infection with human papillomavirus (HPV). Immune checkpoint inhibitors targeting the programmed cell death 1
Externí odkaz: https://doaj.org/article/5b3e3b1bc7294331bf25fd5f151678dd
Zobrazit plný text záznamu
2
Akademický článek
Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab
Autor: Nicolas A. Giraldo, Peter Nguyen, Elizabeth L. Engle, Genevieve J. Kaunitz, Tricia R. Cottrell, Sneha Berry, Benjamin Green, Abha Soni, Jonathan D. Cuda, Julie E. Stein, Joel C. Sunshine, Farah Succaria, Haiying Xu, Aleksandra Ogurtsova, Ludmila Danilova, Candice D. Church, Natalie J. Miller, Steve Fling, Lisa Lundgren, Nirasha Ramchurren, Jennifer H. Yearley, Evan J. Lipson, Mac Cheever, Robert A. Anders, Paul T. Nghiem, Suzanne L. Topalian, Janis M. Taube
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-11 (2018)
Abstract Background We recently reported a 56% objective response rate in patients with advanced Merkel cell carcinoma (MCC) receiving pembrolizumab. However, a biomarker predicting clinical response was not identified. Methods Pretreatment FFPE tumo
Externí odkaz: https://doaj.org/article/76e43af2693646548cca3682365754c1
Zobrazit plný text záznamu
8
Neoadjuvant Nivolumab in Patients with High-risk Nonmetastatic Renal Cell Carcinoma
Autor: Janis M. Taube, Hans J. Hammers, Charles G. Drake, Julie E. Stein, Phillip M. Pierorazio, Alice Pons, Noah M. Hahn, Daniela C. Salles, Hiten D. Patel, Tamara L. Lotan, Michael A. Gorin, Steven P. Rowe, Mohamad E. Allaf, Bruce J. Trock, Thomas R. Nirschl
Publikováno v: European Urology Oncology. 5:113-117
Neoadjuvant immune checkpoint blockade represents a novel approach for potentially decreasing the risk of recurrence in patients with nonmetastatic renal cell carcinoma (RCC). In this early phase clincal tiral, we evaluated the safety and tolerabilit
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6e94f634f464222445746b21feedae0
https://doi.org/10.1016/j.euo.2021.04.002
Zobrazit plný text záznamu
10
Data from Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade
Autor: Janis M. Taube, Suzanne L. Topalian, Drew M. Pardoll, Elizabeth M. Jaffee, Hao Wang, Josephine Feliciano, Mark Yarchoan, Mohamad E. Allaf, Elizabeth D. Thompson, Ashley Cimino-Mathews, Robert A. Anders, Patrick M. Forde, Tricia R. Cottrell, Evan J. Lipson, Julie E. Stein
Purpose:Pathologic response assessment of tumor specimens from patients receiving systemic treatment provides an early indication of therapeutic efficacy and predicts long-term survival. Grading systems for pathologic response were first developed fo
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::306dceea7e36d45e003608408c669dff
https://doi.org/10.1158/1078-0432.c.6530270
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje